353 related articles for article (PubMed ID: 29100397)
1. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.
Kim ST; Klempner SJ; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Lee J
Oncotarget; 2017 Sep; 8(44):77415-77423. PubMed ID: 29100397
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
4. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
5. Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.
Zhang Y; Sun Z; Mao X; Wu H; Luo F; Wu X; Zhou L; Qin J; Zhao L; Bai C
Oncotarget; 2017 Oct; 8(49):85526-85536. PubMed ID: 29156738
[TBL] [Abstract][Full Text] [Related]
6. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Özcan D; Lade-Keller J; Tramm T
Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients with Pancreatic Ductal Adenocarcinoma (PDAC).
Constantin A; Iovănescu V; Cazacu IM; Ungureanu BS; Copăescu C; Stroescu C; Bejinariu N; Săftoiu A
Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204385
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
9. Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival.
Svensson MC; Borg D; Zhang C; Hedner C; Nodin B; Uhlén M; Mardinoglu A; Leandersson K; Jirström K
Front Oncol; 2019; 9():136. PubMed ID: 30931254
[No Abstract] [Full Text] [Related]
10. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
[TBL] [Abstract][Full Text] [Related]
12. The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.
Feng YC; Ji WL; Yue N; Huang YC; Ma XM
Cancer Manag Res; 2018; 10():105-113. PubMed ID: 29403308
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability.
Montella M; Sabetta R; Ronchi A; De Sio M; Arcaniolo D; De Vita F; Tirino G; Caputo A; D'Antonio A; Fiorentino F; Facchini G; Lauro GD; Perdonà S; Ventriglia J; Aquino G; Feroce F; Borges Dos Reis R; Neder L; Brunelli M; Franco R; Zito Marino F
Front Med (Lausanne); 2022; 9():874213. PubMed ID: 35592855
[TBL] [Abstract][Full Text] [Related]
14. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
Kong P; Wang J; Song Z; Liu S; He W; Jiang C; Xie Q; Yang L; Xia X; Xia L
J Cancer; 2019; 10(7):1745-1754. PubMed ID: 31205530
[TBL] [Abstract][Full Text] [Related]
15. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Hacking S; Jin C; Komforti M; Liang S; Nasim M
Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis.
Mamat Yusof MN; Chew KT; Hafizz AMHA; Abd Azman SH; Ab Razak WS; Hamizan MR; Kampan NC; Shafiee MN
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627060
[TBL] [Abstract][Full Text] [Related]
18. DNA mismatch repair system regulates the expression of PD-L1 through DNMTs in cervical cancer.
Guo F; Lu R; Kong W; Anwar M; Feng Y
Cancer Cell Int; 2024 Jan; 24(1):25. PubMed ID: 38200495
[TBL] [Abstract][Full Text] [Related]
19. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Expression and Prognosis of Mismatch Repair Proteins and PD-L1 in Colorectal Cancer in a Chinese Cohort.
Han L; Zhang Y; Li L; Zhang Q; Liu Z; Niu H; Hu J; Ding Z; Shi X; Qian X
Cancer Manag Res; 2023; 15():791-801. PubMed ID: 37575316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
